Increased plasma-borne extracellular vesicles in Multiple Sclerosis - Where did they come from?

K. Groen, S. Burnard, V. E. Maltby, R. J. Scott, L. Tajouri, J. Lechner-Scott

Research output: Contribution to journalMeeting AbstractResearchpeer-review

Abstract

Background:
Extracellular vesicles (EVs) play a crucial role in cell-to-cell communication. An increase in plasma-borne EVs has been observed in Multiple Sclerosis (MS) and since EVs may cross the blood-brain barrier and elicit altered immune responses, EVs may present a link between peripheral inflammation and the
central nervous system.
Objective:
To determine if the cellular origin of plasma-borne EVs differs between MS subtypes and healthy controls (HCs).
Methods:
Platelet-free plasma was obtained from 13 relapsingremitting MS (RRMS), 8 secondary progressive MS (SPMS), and 17 matched HCs, stained with CD235a-APC (erythrocytederived), CD41b-FITC (platelet-derived), CD45-FITC (leukocyte-derived), and CD146-PE (endothelium-derived) antibodies, and analysed on a LSR Fortessa (BD Biosciences). EV gates were set using size reference beads and quantified using CountBright beads (Invitrogen).
Results:
RRMS patients’ endothelium-derived EVs positively correlated with number of relapses (P=0.02415, R=0.619). All EV subpopulations appeared increased in MS, with endotheliumderived EVs being the most abundant (3796±8355 EVs/µl, 3.66- fold, p=0.137), followed by erythrocyte-derived (2704±3729 EVs/µl, 2.65-fold, p=0.064), platelet-derived (2279±1337 EVs/µl, 1.09-fold, ns), and leukocyte-derived EVs (1900±2528 EVs/µl, 2.37-fold, p=0.071). In contrast, platelet-derived EVs were most prevalent in HCs, followed by endothelium-derived, erythrocytederived, and leukocyte-derived EVs. Comparing MS subtypes to HCs, erythrocyte-derived (3.08-fold) and endothelium-derived EVs (2.58-fold) showed greatest increases in RRMS, while endothelium-derived (6.87-fold) and leukocyte-derived EVs (3.51- fold) showed greatest increases in SPMS.
Conclusions: This preliminary data suggests there may be an increase in plasma-borne EVs in MS and monitoring of EV subpopulations may reflect underlying disease processes. Further, increases in EV subpopulations might differ between disease courses.
Disclosures:
Professor J. Lechner-Scott’s institution receives non-directed funding, as well as honoraria for presentations and membership on advisory boards from Sanofi Aventis, Biogen Idec, Bayer Health Care, Merck Serono, Teva, Roche, and
Novartis, Australia. Professor R. Scott has nothing to disclose.
Associate Professor L. Tajouri has nothing to disclose
Original languageEnglish
Article numberO-18
Pages (from-to)443-444
Number of pages2
JournalMultiple Sclerosis Journal
Volume25
Issue number3
DOIs
Publication statusPublished - Mar 2019
EventCongress of the Pan-Asian Committee for Treatment and Research in Multiple Sclerosis (PACTRIMS) - Sydney, Australia
Duration: 1 Nov 20183 Nov 2020

Cite this